To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 June 2023 to Question 188918 on Drugs: Licensing, whether he considers the menopause to be a public health need.

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 June 2023 to Question 188918 on Drugs: Licensing, what criteria his Department uses to determine what conditions are a public health need.

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 June 2023 to Question 188920 on Drugs: Licensing, whether the Medicines and Healthcare products Regulatory Agency plans to prioritise applications for new hormone replacement therapy products, in the context of hormone replacement therapy supply shortages.

There are no formal criteria to prioritise applications for medicines because this is reserved for exceptional circumstances, such as during the COVID-19 pandemic. As previously stated the Medicines and Healthcare products Regulatory Agency (MHRA) collaborates with the Department and National Health Service where a condition that currently does not have any currently licensed medicines, or where there are supply issues with currently licensed medicines.

There are over 70 hormone replacement therapy (HRT) products available in the United Kingdom and the vast majority are in good supply. MHRA regularly engages with the Department to prevent and mitigate supply issues in the short and long term and works with them to ensure decisions are aligned with the wider health sector’s priorities.